Essential Thrombocythemia (ET)
''Essential thrombocytosis (primary thrombocythemia), first described by Epstein and Goedel in 1934, is a nonreactive, chronic myeloproliferative disorder.
Essential thrombocytosis (primary thrombocythemia) is associated with sustained megakaryocyte proliferation that increases the number of circulating platelets. Traditionally, essential thrombocytosis (primary thrombocythemia) was considered a clonal disorder that involved pluripotent stem cells; however, studies have indicated that some patients may have polyclonal hematopoiesis''
Extract of Medscape
VIDEOS
Essential Thrombocythemia for Patients
October 4, 2018, UT Health San Antonio MD Anderson Cancer Center
Current Management of Essential Thrombocythemia - Carlos Besses, MD
December 7, 2017, Cancer Research & Treatment Fund
How Do I Manage My Risk for Clotting As I Age With Essential Thrombocythemia (ET)?
November 30, 2017, Patient Power
Essential Thrombocythemia : Causes, Diagnosis, Symptoms, Treatment, Prognosis
November 18, 2017, Dr. Warraich Health Channel
An Overview of Updated Guidelines in Polycythemia Vera and Essential Thrombocythemia
November 8, 2017, Targeted Oncology
Dr. Mesa on Guideline Updates in Polycythemia Vera and Essential Thrombocythemia
October 8, 2017, OncLiveTV
Essential Thrombocythemia (ET) in Young People: What’s the Treatment Plan?
October 6, 2017, Patient Power
Topical challenges in the management of ET
August 22, 2017, ImedexCME
What Are Common Symptoms of Essential Thrombocythemia (ET)?
March 17, 2017, Voices of MPN
What Is the Life Span and Quality of Life for a Patient With Essential Thrombocythemia?
December 14, 2016, Patient Power
Is Essential Thrombocythemia (ET) Related to High Blood Pressure?
December 5, 2016, Patient Power
Kate’s 7-Year Journey to ET Diagnosis
October 14, 2015, Patient Power
What is Essential Thrombocythemia?
June 8, 2015, deborah thompkins
The Aim of Essential Thrombocythemia (ET) Treatment
August 23, 2016, Patient Power
Covering Treatment Choices for Essential Thrombocythemia (ET)
February 29, 2016, Patient Power
Essential Thrombocythemia Update 2015
December 16, 2014, Mayo Clinic
Essential Thrombocythemia Update 2014 - Mayo Clinic
December 17, 2013, Mayo Clinic
Living with (Primary)Essential Thrombocythemia
August 20, 2012, Thrombocythemia
Essential Thrombocythemia Updates 2012 – Mayo Clinic
March 15, 2012, Mayo Clinic
Essential Thrombocythemia (2009) - Mayo Clinic
December 4, 2009, Mayo Clinic
ARTICLES
An Unexpected New Lung Function Has Been Found - They Make Blood
March 24, 2017, Science Alert
Genetic Puzzle Piece for Blood Cancers Found
December 12, 2013, MedPage Today
Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms
2013, Journal Blood
The Genomic Landscape of Myeloproliferative Neoplasms: Somatic CALR Mutations in the Majority of JAK2-Wildtype Patients
2013, Journal Blood
Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F
September 5, 2013, Experimental Hematology & Oncology
Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.
June 2013, PublMed
Pregnancy and essential thrombocytemia
March 29, 2011, PublMed Central
New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia
January 1, 2008, Hematology
Essential thrombocythemia (Pr Jean Brière – France)
January 8, 2007, PublMed Central
An Unexpected New Lung Function Has Been Found - They Make Blood
March 24, 2017, Science Alert
Genetic Puzzle Piece for Blood Cancers Found
December 12, 2013, MedPage Today
Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms
2013, Journal Blood
The Genomic Landscape of Myeloproliferative Neoplasms: Somatic CALR Mutations in the Majority of JAK2-Wildtype Patients
2013, Journal Blood
Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F
September 5, 2013, Experimental Hematology & Oncology
Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.
June 2013, PublMed
Pregnancy and essential thrombocytemia
March 29, 2011, PublMed Central
New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia
January 1, 2008, Hematology
Essential thrombocythemia (Pr Jean Brière – France)
January 8, 2007, PublMed Central
